Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 4/2008

01-11-2008 | Original paper

Decision-analytical modelling in health-care economic evaluations

Authors: Xin Sun, Thomas Faunce

Published in: The European Journal of Health Economics | Issue 4/2008

Login to get access

Abstract

Objective

Decision-analytical modelling is widely used in health-care economic evaluations, especially in situations where evaluators lack clinical trial data, and in circumstances where such evaluations factor into reimbursement pricing decisions. This paper aims to improve the understanding and use of modelling techniques in this context, with particular emphasis on Markov modelling.

Methods

We provide an overview, in this paper, of the principles and methodological details of decision-analytical modelling. We propose a common route for practicing modelling that accommodates any type of decision-analytical modelling techniques. We use the treatment of chronic hepatitis B as an example to indicate the process of development, presentation and analysis of the Markov model, and discuss the strengths, weaknesses and pitfalls of different approaches.

Conclusions

Good practice of modelling requires careful planning, conduct and analysis of the model, and needs input from modellers and users.
Literature
1.
Sun, X., Orlewska, E., Li, Y.P., Cheng, G., Yang, H.: Methods for economic evaluation of marketed medicines II: Conducting primary economic evaluation. Chin J Evid Based Med 6, 218–223 (2006)
2.
Commonwealth Department of Health Housing and Community Services: Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Including Major Submissions Involving Economic Analyses (draft). Canberra (2006)
3.
Food and Drug Administration: Principles for the Review of Pharmacoeconomic Promotion. Rockville: FDA (1995)
4.
Brennan, A., Akehurst, R.: Modelling in health economic evaluation: What is its place? What is its value? Pharmacoeconomics 17(5), 445–459 (2000)CrossRef
5.
Buxton, M.J., Drummond, M.F., Van Hout, B.A., Prince, R.L., Sheldon, T.A., Szucs, T., Vray, M.: Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6, 217–227 (1997)CrossRef
6.
Brennan, A., Akehurst, R.: Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 17, 445–459 (2000)CrossRef
7.
Sculpher, M., Drummond, M., Buxton, M.: The interactive use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 2, 26–30 (1997)
8.
Chilcott, J.B., Brennan, A., Booth, A., Karnon, J., Tappenden, P.: The role of modelling in prioritising and planning clinical trials. Health Technol Assess 7, 1–125 (2003)
9.
Karnon, J.: Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ 12, 837–848 (2003)CrossRef
10.
Orlewska, E.: The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland. Value Health 5, 405–421 (2002)CrossRef
11.
Wright, J.L., Wessells, H., Nathens, A.B., Hollingworth, W.: What is the most cost-effective treatment for 1 to 2-cm bulbar urethral strictures: societal approach using decision analysis. Urology 67, 889–893 (2006)CrossRef
12.
Chambers, M.G., Koch, P., Hutton, J.: Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 5, 82–97 (2002)
13.
Spiegelhalter, D.J., Abrams, K.R., Myles, J.P.: Bayesian Approaches to Clinical Trials and Health-Care Evaluation. London: Wiley (2004)
14.
Breese, J.S.: Construction of belief and decision networks. Comput Intel 8, 624–647 (1992)CrossRef
15.
Powell, C.: The Delphi technique: myths and realities. J Adv Nurs 41, 376–382 (2003)CrossRef
16.
van Steenkiste, B.C., Jacobs, J.E., Verheijen, N.M., Levelink, J.H., Bottema B.J.A.M.: A Delphi technique as a method for selecting the content of an electronic patient record for asthma. Int J Med Inf 65, 7–16 (2002)CrossRef
17.
Salomon, J.A., Murray, C.J.L.: A multi-method approach to measuring health-state valuations. Health Econ 13, 281–290 (2004)
18.
Brazier, J., Deverill, M., Green, C., Harper, R., Booth, A.: A review of the use of health status measures in economic evaluation. Health Technol Assess 3 (9) (1999)
19.
Briggs, A., Sculpher, M., Buxton, M.: Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 3, 95–104 (1994)CrossRef
20.
Briggs, H.A.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17, 479–500 (2000)CrossRef
21.
Nuijten, M.J.C.: Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations. Pharmacoeconomics 22, 759–769 (2004)CrossRef
22.
Philips, Z., Ginnelly, L., Sculpher, M., Claxton, K., Golder, S., Riemsma, R.: Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 8(36) (2004)
23.
Sonnenberg, F.A., Roberts, M.S., Tsevat, J., Wong, J.B., Barry, M., Ken, D.: Toward a peer review process for medical decision analysis models. Med Care 32, JS52–JS64 (1994)CrossRef
24.
Briggs, A., Sculpher, M.: An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 13, 397–409 (1998)CrossRef
25.
Shamir, R., Hernell, O., Leshno, M.: Cost-effectiveness analysis of screening for celiac disease in the adult population. Med Decis Making 26, 282–293 (2006)CrossRef
26.
CDC Diabetes Cost-effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 87, 2542–2551 (2002)CrossRef
27.
Canadian Coordinating Office for Health Technology Assessment: Guidelines for economic evaluation of pharmaceuticals: Canada, 3rd edn. Ottawa: Canadian Agency for Drugs and Technologies in Health (2006)
28.
Weistein, M.C., O’Brien, B., Hornberger, J., Jackson, J., Johannesson, M., McCabe, C.: Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices-modeling studies. Value Health 6, 9–17 (2003)CrossRef
29.
Manca, A., Rice, N., Sculpher, M.J., Briggs, A.H.: Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 14, 471–485 (2005)
30.
Pharoah, P.D., Hollingworth, W.: Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 312, 1443–1448 (1996)
31.
Nuijten, M.J.C., Hardens, M.: Measuring sensitivity in pharmacoeconomic studies: an integration of point-sensitivity and range sensitivity. Pharmacoeconomics 12, 555–564 (1997)CrossRef
32.
Heitjan, D.F., Li, H.: Bayesian estimation of cost-effectiveness: an importance-sampling approach. Health Econ 13, 191–198 (2004)CrossRef
33.
Vanness, D.J., Kim, W.R.: Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation. Health Econ 11, 551–566 (2002)CrossRef
34.
Briggs, A.H., Gray, A.M.: Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 3(2) (1999)
35.
Stinnett, A.A., Mullahy, J.: Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Making 18(Suppl 2), S65–S80 (1998)
36.
Gafni, A., Birch, S.: Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Can Med Assoc J 148, 913–917 (1993)
37.
Fenwick, E., Marshall, D.A., Levy, A.R., Nichol, G.: Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 6, 52 (2006)CrossRef
38.
Sendi, P.P., Briggs, A.H.: Affordability and cost-effectiveness: Decision-making on the cost-effectiveness plane. Health Econ 10, 675–680 (2001)CrossRef
39.
Bala, M.V., Mauskopf, J.A.: Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts. Pharmacoeconomics 24, 345–354 (2006)CrossRef
Metadata
Title
Decision-analytical modelling in health-care economic evaluations
Authors
Xin Sun
Thomas Faunce
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 4/2008
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-007-0078-x

Other articles of this Issue 4/2008

The European Journal of Health Economics 4/2008 Go to the issue

Original paper

Expanding access to primary care without additional budgets? A case study from Burkina Faso

Original paper

Nurses’ intentions to leave nursing in Finland

Original paper

Health insurance theory: the case of the missing welfare gain

Original paper

The societal cost of alcohol consumption: an estimation of the economic and human cost including health effects in Sweden, 2002

Original paper

Discarded cellular components and the technical efficiency of component preparation

Original paper

Lessons for health care reform from the less developed world: the case of the Philippines